Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2019

Open Access 01-12-2019 | Hypertension | Original investigation

sRAGE and early signs of cardiac target organ damage in mild hypertensives

Authors: Andrea Maria Maresca, Luigina Guasti, Sara Bozzini, Christian Mongiardi, Nicolò Tandurella, Rossana Corso, Francesco G. Zerba, Alessandro Squizzato, Leonardo Campiotti, Francesco Dentali, Catherine Klersy, Anna M. Grandi, Colomba Falcone

Published in: Cardiovascular Diabetology | Issue 1/2019

Login to get access

Abstract

Background

Soluble Receptor for Advanced Glycation End Products (sRAGE) may be considered a marker inversely related to inflammation and its participation has been established in patients with advanced atherosclerotic vascular diseases. However, it is still unknown whether sRAGE reduction could be early metabolic change in the first stage of hypertension and initial hypertension-associated cardiac damage. We sought to determine the sRAGE values in otherwise healthy, untreated and recently diagnosed mild hypertensives and evaluate their association with blood pressure (BP) values, metabolic parameters, and with subclinical initial signs of cardiac target organ damage (TOD).

Methods

sRAGE were measured in 100 hypertensive and 100 normotensive subjects matched for age, gender and body mass index (BMI), submitted to a clinic visit and both ambulatory BP monitoring and echocardiography to determine the presence of initial cardiac TOD (presence of signs of left ventricular hypertrophy: left ventricular mass indexed for height2.7 (LVMi) > 48 g/m2.7 for men and > 44 g/m2.7 for women and/or increased left atrial volume 4-chamber indexed for body surface area (LAVi) > 34 ml/m2).

Results

sRAGE levels were similar between hypertensive and normotensive subjects and were not significantly correlated with office and 24-h BPs values. However, when subgrouping the hypertensive patients in Hyp-TOD and Hyp-withoutTOD, sRAGE was found to be different among the three groups (p = 0.030), being lower in the Hyp-TOD group than the values of both Hyp-withoutTOD (p = 0.038) and normotensives (p = 0.038). In hypertensive patients sRAGE was negatively related with both LVMi (r = − 0.239, p = 0.034) and LAVi (r = − 0.315, p = 0.005) and was independently related to cardiac TOD also in multivariable analysis.

Conclusions

In this population of mild hypertensives, low circulating sRAGE may be a very early marker of initial TOD, suggesting the possible participation of oxidative stress in initial cardiac changes in human hypertension.
Appendix
Available only for authorised users
Literature
1.
go back to reference Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. 2014;20:2395–23402.PubMedCrossRef Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des. 2014;20:2395–23402.PubMedCrossRef
2.
go back to reference Al Rifai M, Schneider AL, Alonso A, Maruthur N, Parrinello CM, Astor BC, Hoogeveen RC, Soliman EZ, Chen LY, Ballantyne CM, Halushka MK, Selvin E. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015;29:180–5.PubMedCrossRef Al Rifai M, Schneider AL, Alonso A, Maruthur N, Parrinello CM, Astor BC, Hoogeveen RC, Soliman EZ, Chen LY, Ballantyne CM, Halushka MK, Selvin E. sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications. 2015;29:180–5.PubMedCrossRef
3.
go back to reference Falcone C, Emanuele E, D’Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–7.PubMedCrossRef Falcone C, Emanuele E, D’Angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol. 2005;25:1032–7.PubMedCrossRef
4.
go back to reference Falcone C, Buzzi MP, Bozzini S, TALENTInvestigators, et al. Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk. J Nephrol. 2013;26:144–55.PubMedCrossRef Falcone C, Buzzi MP, Bozzini S, TALENTInvestigators, et al. Relationship between sRAGE and eotaxin-3 with CRP in hypertensive patients at high cardiovascular risk. J Nephrol. 2013;26:144–55.PubMedCrossRef
5.
go back to reference Geroldi D, Falcone C, Emanuele E, D’Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725–9.PubMedCrossRef Geroldi D, Falcone C, Emanuele E, D’Angelo A, Calcagnino M, Buzzi MP, Scioli GA, Fogari R. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23:1725–9.PubMedCrossRef
6.
go back to reference Falcone C, Bozzini S, Guasti L, D’Angelo A, Capettini AC, Paganini EM, Falcone R, Moia R, Gazzaruso C, Pelissero G. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. Sci World J. 2013;9(2013):584504. Falcone C, Bozzini S, Guasti L, D’Angelo A, Capettini AC, Paganini EM, Falcone R, Moia R, Gazzaruso C, Pelissero G. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease. Sci World J. 2013;9(2013):584504.
7.
go back to reference Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol. 2014;23:11–6.PubMedPubMedCentralCrossRef Prasad K. Low levels of serum soluble receptors for advanced glycation end products, biomarkers for disease state: myth or reality. Int J Angiol. 2014;23:11–6.PubMedPubMedCentralCrossRef
8.
go back to reference Reichert S, Triebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A, Schulz S. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9.PubMedCrossRef Reichert S, Triebert U, Santos AN, Hofmann B, Schaller HG, Schlitt A, Schulz S. Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis. 2017;266:234–9.PubMedCrossRef
9.
go back to reference Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRef Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F. Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281–357.CrossRef
10.
go back to reference Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71:e13–115.PubMed Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2017;71:e13–115.PubMed
11.
go back to reference Cuspidi C, Valerio C, Sala C, Esposito A, Masaidi M, Negri F, Zanchetti A, Mancia G. Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure. Blood Press Monit. 2008;13:7–13.PubMedCrossRef Cuspidi C, Valerio C, Sala C, Esposito A, Masaidi M, Negri F, Zanchetti A, Mancia G. Prevalence and correlates of multiple organ damage in a never-treated hypertensive population: role of ambulatory blood pressure. Blood Press Monit. 2008;13:7–13.PubMedCrossRef
12.
go back to reference Lehmann N, Erbel R, Mahabadi AA, Kälsch H, Möhlenkamp S, Moebus S, Stang A, Roggenbuck U, Strucksberg KH, Führer-Sakel D, Dragano N, Budde T, Seibel R, Grönemeyer D, Jöckel KH, Heinz Nixdorf Recall Study Investigators. Accelerated progression of coronary artery calcification in hypertension but also prehypertension. J Hypertens. 2016;34:2233–42.PubMedCrossRef Lehmann N, Erbel R, Mahabadi AA, Kälsch H, Möhlenkamp S, Moebus S, Stang A, Roggenbuck U, Strucksberg KH, Führer-Sakel D, Dragano N, Budde T, Seibel R, Grönemeyer D, Jöckel KH, Heinz Nixdorf Recall Study Investigators. Accelerated progression of coronary artery calcification in hypertension but also prehypertension. J Hypertens. 2016;34:2233–42.PubMedCrossRef
13.
go back to reference Cuspidi C, Tadic M, Sala C, Grassi G. How to identify hypertensive patients at high cardiovascular risk? The role of echocardiography. High Blood Press Cardiovasc Prev. 2015;22:113–7.PubMedCrossRef Cuspidi C, Tadic M, Sala C, Grassi G. How to identify hypertensive patients at high cardiovascular risk? The role of echocardiography. High Blood Press Cardiovasc Prev. 2015;22:113–7.PubMedCrossRef
14.
go back to reference Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.PubMedCrossRef Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F, American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.PubMedCrossRef
15.
go back to reference Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.PubMedCrossRef Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2015;28:1–39.PubMedCrossRef
16.
go back to reference Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRef Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRef
17.
go back to reference Klahr S, Levey AS, Beck GJ, et al. For the Modification of Diet in Renal Disease Study Group: the effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–84.PubMedCrossRef Klahr S, Levey AS, Beck GJ, et al. For the Modification of Diet in Renal Disease Study Group: the effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–84.PubMedCrossRef
18.
go back to reference Liu Q, Chen HB, Luo M, Zheng H. Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients. Genet Mol Res. 2016;14:15. Liu Q, Chen HB, Luo M, Zheng H. Serum soluble RAGE level inversely correlates with left ventricular hypertrophy in essential hypertension patients. Genet Mol Res. 2016;14:15.
19.
go back to reference Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2012;22:748–55.PubMedCrossRef Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C. Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis. 2012;22:748–55.PubMedCrossRef
20.
go back to reference Moriya S, Yamazaki M, Murakami H, Maruyama K, Uchiyama S. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE. J Stroke Cerebrovasc Dis. 2014;23(10):2540–6.PubMedCrossRef Moriya S, Yamazaki M, Murakami H, Maruyama K, Uchiyama S. Two soluble isoforms of receptors for advanced glycation end products (RAGE) in carotid atherosclerosis: the difference of soluble and endogenous secretory RAGE. J Stroke Cerebrovasc Dis. 2014;23(10):2540–6.PubMedCrossRef
21.
go back to reference Wang Y, Zhang W, Zhao H, Wang Y, Lu C, Li X, Wang Y, Xiao Y, Wang Y, Wang B. Fasting blood soluble RAGE may be causally implicated in impaired glucose metabolism in Chinese patients with primary hypertension. Gene. 2018;10(639):11–7.CrossRef Wang Y, Zhang W, Zhao H, Wang Y, Lu C, Li X, Wang Y, Xiao Y, Wang Y, Wang B. Fasting blood soluble RAGE may be causally implicated in impaired glucose metabolism in Chinese patients with primary hypertension. Gene. 2018;10(639):11–7.CrossRef
22.
go back to reference Heier M, Margeirsdottir HD, Gaarder M, Stensæth KH, Brunborg C, Torjesen PA, Seljeflot I, Hanssen KF, Dahl-Jørgensen K. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.PubMedPubMedCentralCrossRef Heier M, Margeirsdottir HD, Gaarder M, Stensæth KH, Brunborg C, Torjesen PA, Seljeflot I, Hanssen KF, Dahl-Jørgensen K. Soluble RAGE and atherosclerosis in youth with type 1 diabetes: a 5-year follow-up study. Cardiovasc Diabetol. 2015;14:126.PubMedPubMedCentralCrossRef
23.
go back to reference Paradela-Dobarro B, Fernández-Trasancos Á, Bou-Teen D, Eiras S, González-Ferreiro R, Agra RM, Varela-Román A, Castro-Pais AI, Carreira MC, Casanueva FF, Álvarez E, González-Juanatey JR. Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition. Cardiovasc Diabetol. 2017;16(1):115.PubMedPubMedCentralCrossRef Paradela-Dobarro B, Fernández-Trasancos Á, Bou-Teen D, Eiras S, González-Ferreiro R, Agra RM, Varela-Román A, Castro-Pais AI, Carreira MC, Casanueva FF, Álvarez E, González-Juanatey JR. Evolution and bad prognostic value of advanced glycation end products after acute heart failure: relation with body composition. Cardiovasc Diabetol. 2017;16(1):115.PubMedPubMedCentralCrossRef
24.
go back to reference Li B, Chi RF, Qin FZ, Guo XF. Distinct changes of myocyte autophagy during myocardial hypertrophy and heart failure: association with oxidative stress. Exp Physiol. 2016;101:1050–63.PubMedCrossRef Li B, Chi RF, Qin FZ, Guo XF. Distinct changes of myocyte autophagy during myocardial hypertrophy and heart failure: association with oxidative stress. Exp Physiol. 2016;101:1050–63.PubMedCrossRef
25.
go back to reference Wang JP, Chi RF, Wang K, Ma T, Guo XF, Zhang XL, Li B, Qin FZ, Han XB, Fan BA. Oxidative stress impairs myocyte autophagy, resulting in myocyte hypertrophy. Exp Physiol. Exp Physiol. 2018;103(4):461–72.PubMedCrossRef Wang JP, Chi RF, Wang K, Ma T, Guo XF, Zhang XL, Li B, Qin FZ, Han XB, Fan BA. Oxidative stress impairs myocyte autophagy, resulting in myocyte hypertrophy. Exp Physiol. Exp Physiol. 2018;103(4):461–72.PubMedCrossRef
26.
go back to reference Ren X, Ren L, Wei Q, Shao H, Chen L, Liu N. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017;16(1):52.PubMedPubMedCentralCrossRef Ren X, Ren L, Wei Q, Shao H, Chen L, Liu N. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017;16(1):52.PubMedPubMedCentralCrossRef
27.
go back to reference Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16:120.PubMedPubMedCentralCrossRef Karam BS, Chavez-Moreno A, Koh W, Akar JG, Akar FG. Oxidative stress and inflammation as central mediators of atrial fibrillation in obesity and diabetes. Cardiovasc Diabetol. 2017;16:120.PubMedPubMedCentralCrossRef
28.
go back to reference Yang PS, Kim TH, Uhm JS, Park S, Joung B, Lee MH, Pak HN. High plasma level of soluble RAGE is independently associated with a low recurrence of atrial fibrillation after catheter ablation in diabetic patient. Europace. 2016;18:1711–8.PubMedCrossRef Yang PS, Kim TH, Uhm JS, Park S, Joung B, Lee MH, Pak HN. High plasma level of soluble RAGE is independently associated with a low recurrence of atrial fibrillation after catheter ablation in diabetic patient. Europace. 2016;18:1711–8.PubMedCrossRef
29.
go back to reference Di Pino A, Mangiafico S, Urbano F, Scicali R, Scandura S, D’Agate V, Piro S, Tamburino C, Purrello F, Rabuazzo AM. HbA1c identifies subjects with prediabetes and subclinical left ventricular diastolic dysfunction. J Clin Endocrinol Metab. 2017;102:3756–64.PubMedCrossRef Di Pino A, Mangiafico S, Urbano F, Scicali R, Scandura S, D’Agate V, Piro S, Tamburino C, Purrello F, Rabuazzo AM. HbA1c identifies subjects with prediabetes and subclinical left ventricular diastolic dysfunction. J Clin Endocrinol Metab. 2017;102:3756–64.PubMedCrossRef
30.
go back to reference Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, Maio RC, Legnaro M, Schembri L, Dentali F, Grandi AM, Guasti L. Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Cardiovasc Diabetol. 2012;11:153.PubMedPubMedCentralCrossRef Marino F, Maresca AM, Cosentino M, Castiglioni L, Rasini E, Mongiardi C, Maio RC, Legnaro M, Schembri L, Dentali F, Grandi AM, Guasti L. Angiotensin II type 1 and type 2 receptor expression in circulating monocytes of diabetic and hypercholesterolemic patients over 3-month rosuvastatin treatment. Cardiovasc Diabetol. 2012;11:153.PubMedPubMedCentralCrossRef
31.
go back to reference Marino F, Guasti L, Tozzi M, Consuelo Maio R, Castiglioni L, Rasini E, Schembri L, Maroni L, Legnaro M, De Leo A, Piffaretti G, Castelli P, Venco A, Lecchini S, Cosentino M. Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2009;54:520–5.PubMedCrossRef Marino F, Guasti L, Tozzi M, Consuelo Maio R, Castiglioni L, Rasini E, Schembri L, Maroni L, Legnaro M, De Leo A, Piffaretti G, Castelli P, Venco A, Lecchini S, Cosentino M. Angiotensin type 1 receptor expression and interleukin-8 production in polymorphonuclear leukocytes of patients with peripheral arterial disease. J Cardiovasc Pharmacol. 2009;54:520–5.PubMedCrossRef
32.
go back to reference Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, Castiglioni L, Klersy C, Gaudio G, Grandi AM, Lecchini S, Venco A. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J. 2008;29:1118–26.PubMedCrossRef Guasti L, Marino F, Cosentino M, Maio RC, Rasini E, Ferrari M, Castiglioni L, Klersy C, Gaudio G, Grandi AM, Lecchini S, Venco A. Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up. Eur Heart J. 2008;29:1118–26.PubMedCrossRef
33.
go back to reference Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, Guasti L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardio version. A systematic review and meta-analysis. Thromb Haemost. 2011;106:363–70.PubMedCrossRef Dentali F, Gianni M, Squizzato A, Ageno W, Castiglioni L, Maroni L, Hylek EM, Grandi AM, Cazzani E, Venco A, Guasti L. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardio version. A systematic review and meta-analysis. Thromb Haemost. 2011;106:363–70.PubMedCrossRef
34.
go back to reference Falcone C, Buzzi MP, Bozzini S, Boiocchi C, D’Angelo A, Schirinzi S, Esposito C, Torreggiani M, Choi J, Ochan Kilama M, Mancia G. Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. Mediators Inflamm. 2012;2012:874149.PubMedPubMedCentralCrossRef Falcone C, Buzzi MP, Bozzini S, Boiocchi C, D’Angelo A, Schirinzi S, Esposito C, Torreggiani M, Choi J, Ochan Kilama M, Mancia G. Microalbuminuria and sRAGE in high-risk hypertensive patients treated with nifedipine/telmisartan combination treatment: a substudy of TALENT. Mediators Inflamm. 2012;2012:874149.PubMedPubMedCentralCrossRef
35.
go back to reference Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor- mediated cardiovascular disease. Curr Pharm Des. 2017;23:937–43.PubMedCrossRef Prasad K, Tiwari S. Therapeutic interventions for advanced glycation-end products and its receptor- mediated cardiovascular disease. Curr Pharm Des. 2017;23:937–43.PubMedCrossRef
Metadata
Title
sRAGE and early signs of cardiac target organ damage in mild hypertensives
Authors
Andrea Maria Maresca
Luigina Guasti
Sara Bozzini
Christian Mongiardi
Nicolò Tandurella
Rossana Corso
Francesco G. Zerba
Alessandro Squizzato
Leonardo Campiotti
Francesco Dentali
Catherine Klersy
Anna M. Grandi
Colomba Falcone
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2019
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-019-0821-5

Other articles of this Issue 1/2019

Cardiovascular Diabetology 1/2019 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.